drugset / Trial / NCT00074035
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Phase 2
Completed
39 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells. PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host disease that is refractory (not responsive) to treatment with steroids.
Timeline
- Start
- 2003-12
- Primary completion
- 2008-08
- Completion
- 2014-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentostatin | Small molecule | 4 mg/m2 | Intravenous |